Bloomios, Inc. (OTCPK: BLMS)
Health Care · Pharmaceuticals · US
$0.00
— today · +200.0% 1Y
Bloomios, Inc. (OTCPK: BLMS) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $20.36K and employs 23 people.
Over the last twelve months the share price has gained 200.0%, trading between 0.00 and 0.00.
Tweenvest scores Bloomios, Inc. across four factors: quality 29/100, value 48/100. Its strongest factor is value.
BLMS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $20.36K
- Revenue (TTM)
- $8.23M
- P/E
- —
- EPS
- -1.76
- Dividend yield
- —
- Beta (5Y)
- -0.45
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 67.87M
- Employees
- 23
- Next earnings
- —
About Bloomios, Inc.
Bloomios, Inc. manufactures, markets, and distributes cannabidiol products. The company’s product categories include edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages, and pet treats. It sells its hemp derived supplements and cosmetic products through wholesale and retail distribution channels. The company was formerly known as XLR Medical Corp. and changed its name to Bloomios, Inc. in April 2021. Bloomios, Inc. was incorporated in 2001 and is headquartered in Santa Barbara, California.
- ISIN
- US0948571098
- Founded
- 2001
- Listed since
- Apr 22, 2003
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.